Beigene (NASDAQ:BGNE) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “

BGNE has been the topic of several other reports. Maxim Group restated a “buy” rating and issued a $77.00 price objective on shares of Beigene in a report on Monday, September 11th. Cowen restated a “buy” rating on shares of Beigene in a report on Monday, December 11th. Morgan Stanley restated an “overweight” rating and issued a $95.00 price objective (up from $87.00) on shares of Beigene in a report on Friday, October 6th. Robert W. Baird restated a “neutral” rating and issued a $83.00 price objective (up from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Finally, ValuEngine lowered shares of Beigene from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $96.67.

Shares of Beigene (NASDAQ BGNE) traded down $1.11 during mid-day trading on Monday, hitting $97.41. 171,053 shares of the stock traded hands, compared to its average volume of 158,580. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33. Beigene has a 52-week low of $30.37 and a 52-week high of $118.95. The firm has a market cap of $4,430.00 and a price-to-earnings ratio of -74.36.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same quarter in the prior year, the company posted ($1.08) earnings per share. analysts forecast that Beigene will post -2.04 EPS for the current fiscal year.

In other Beigene news, CEO John Oyler sold 20,137 shares of the stock in a transaction that occurred on Tuesday, December 26th. The shares were sold at an average price of $96.46, for a total transaction of $1,942,415.02. Following the sale, the chief executive officer now directly owns 110,179 shares in the company, valued at approximately $10,627,866.34. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Jane Huang sold 1,000 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $98.00, for a total transaction of $98,000.00. Following the sale, the chief marketing officer now owns 1,000 shares in the company, valued at $98,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 483,482 shares of company stock worth $42,139,474. 19.90% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in shares of Beigene in the 2nd quarter valued at approximately $111,000. Quantbot Technologies LP purchased a new stake in shares of Beigene in the 3rd quarter valued at approximately $160,000. Profund Advisors LLC purchased a new stake in shares of Beigene in the 2nd quarter valued at approximately $248,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Beigene in the 3rd quarter valued at approximately $248,000. Finally, Aperio Group LLC purchased a new stake in shares of Beigene in the 3rd quarter valued at approximately $301,000. 55.32% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-investment-research-downgrades-beigene-bgne-to-sell/1798847.html.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Get a free copy of the Zacks research report on Beigene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with Analyst Ratings Network's FREE daily email newsletter.